Login to Your Account

Financings Roundup

HC Royalty Inks Hefty Deals to Propel Nuron and Raptor

By Marie Powers
Staff Writer

Friday, December 21, 2012

HealthCare Royalty Partners II LP closed an $80 million financing with privately held Nuron Biotech Inc. that included a $30 million equity investment and a $50 million synthetic royalty agreement linked to future sales of Meningitec, a vaccine Nuron acquired earlier this month from Pfizer Inc., and its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription